Innovation and Enterprise

There has never been a better time to pursue commercialisation of research, and there is no better place than the Wellcome Genome Campus to harness the intellectual property (IP) of genomics.

Already, venture capitalists and large companies are recognising our potential for rapid development of ideas and the expertise of our scientists in a setting of world class facilities and knowledge here in Hinxton. Commercial enterprises are co-locating here and embedding staff within the Campus Institutes to harness the value in collaboration and knowledge sharing.

At the Wellcome Genome Campus we have a culture where innovation is seen as an extension of our science, rather than just a revenue generator. Our academic researchers are encouraged to maximise the potential of their IP through partnerships with industry, and they are supported by mentors from industry. Alongside regular scientific activity, creating or working for a company is seen as a mark of success and offers the opportunity for academics to work with some of the best business minds in the world.

Hot-desking for entrepreneurs and innovators

Individual entrepreneurs and innovators who are applying a genomics or a bioinformatics focus to their work are invited to join the vibrant community of companies here on Campus, and to enjoy many of the benefits of Campus life.

Find out more


The Campus is a collaborative global hub bringing together institutes and industry. Companies are locating their teams here on Campus; in the BioData Innovation Centre, in the EMBL-EBI innovation space and embedding their staff within EMBL-EBI and the Wellcome Sanger Institute.

COSMIC case study commercialising databases technology transfer

Commercialising Science: CASE STUDIES

How do you protect and commercialise a large data source for the benefit of researchers and industry working to improve cancer treatments? Find out how the Wellcome Sanger Institute's Enterprise & Innovation and COSMIC Teams solved this problem.

Read about COSMIC now
Jeff Barratt Open Targets

Pharmaceutical companies urgently need to improve their success rate in developing new drugs and are increasingly realising that the fastest route to success is through collaboration. Open Targets is a new type of public-private initiative: we're trying to eliminate barriers by having scientists from academia and industry work side by side to translate genomic discoveries into new medicines.

Jeff Barrett, Former Director of Open Targets and Group Leader, Wellcome Sanger Institute

Locate here

The Wellcome Genome Campus is the largest hub for genomics research, bioinformatics, and associated commercial and engagement activities, in the world.

Learn more